{"id":9154,"date":"2018-04-20T08:00:00","date_gmt":"2018-04-20T06:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/"},"modified":"2018-04-20T08:00:00","modified_gmt":"2018-04-20T06:00:00","slug":"irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/","title":{"rendered":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning 2017"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

IRLAB meddelar att \u00c5rsredovisning 2017 nu finns tillg\u00e4nglig p\u00e5 bolagets webbplats.<\/strong><\/div>\n

F\u00f6r mer information och nedladdning av \u00e5rsredovisningen h\u00e4nvisas till www.irlab.se\/investor-relations\/financial-reports\/<\/a>.<\/span><\/p>\n

\n

F\u00f6r vidare information<\/strong><\/p>\n

Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Tel: +46 730 75 77 01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\u00a0
E-post: nicholas.waters@irlab.se<\/a><\/p>\n

Viktor Siewertz, CFO\u00a0
Tel: +46 727 10 70 70\u00a0
E-post: viktor.siewertz@irlab.se<\/a><\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

IRLAB \u00e4r ett forsknings- och utvecklingsbolag, listat p\u00e5 Nasdaq First North Premier som fokuserar p\u00e5 utveckling av nya l\u00e4kemedel f\u00f6r behandling av neurodegenerativa sjukdomar, i synnerhet Parkinsons sjukdom och demens.<\/p>\n

IRLAB har tv\u00e5 kliniska l\u00e4kemedelskandidater, IRL752 och IRL790, inriktade mot medicinska behov vid Parkinsons sjukdom, samt ytterligare projekt i preklinisk fas.<\/p>\n

IRLAB:s forskning syftar till att uppt\u00e4cka och utveckla nya l\u00e4kemedelskandidater f\u00f6r behandling av hj\u00e4rnans sjukdomar, d\u00e4r stora medicinska behov idag f\u00f6religger. Med hj\u00e4lp av den unika systembiologiska forskningsplattformen, ISP, uppt\u00e4cks dess nya behandlingsprinciper.<\/p>\n

IRLAB \u00e4r baserat i G\u00f6teborg. IRLAB:s verksamhet bedrivs huvudsakligen genom dotterbolaget Integrative Research Laboratories Sweden AB.<\/p>\n

F\u00f6r mer information, v\u00e4nligen bes\u00f6k\u00a0www.irlab.se<\/a>.<\/p>\n<\/div>\n

[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"

IRLAB meddelar att \u00c5rsredovisning 2017 nu finns tillg\u00e4nglig p\u00e5 bolagets webbplats.<\/p>\n","protected":false},"template":"","class_list":["post-9154","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-regulatory-vpml_sv"],"acf":[],"yoast_head":"\nIRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning 2017 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning 2017 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB meddelar att \u00c5rsredovisning 2017 nu finns tillg\u00e4nglig p\u00e5 bolagets webbplats.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/\",\"name\":\"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning 2017 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2018-04-20T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning 2017\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning 2017 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning 2017 - IRLAB","og_description":"IRLAB meddelar att \u00c5rsredovisning 2017 nu finns tillg\u00e4nglig p\u00e5 bolagets webbplats.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/","name":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning 2017 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2018-04-20T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-2017\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning 2017"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}